Molecular diagnostics (MDx) company Genetic Signatures Ltd will exhibit at the 24th International Molecular Medicine TRI-Conference (MMTC) in San Francisco, CA on 20th–22nd February 2017.
Genetic Signatures will be exhibiting their novel products for the detection of infectious diseases, including reagents for diagnosing bacterial, viral and protozoan causes of gastroenteritis, respiratory infections and Sexually Transmitted Infections. These reagents are based on the company’s proprietary 3base™ technology, allowing for more efficient detection of infectious microorganisms.
Visit Genetic Signatures at Booth 09 at MMTC 2017 for more information.
About MMTC 2017: MMTC also known as Tri-Con is an annual precision medicine event attracting over 3,500 senior level scientists and executives focused in the areas of Molecular Medicine specifically on Discovery, Genomics, Diagnostics and Informatics.
About Genetic Signatures Limited: Genetic Signatures is a specialist molecular diagnostics (MDx) company focused on the development and commercialisation of its proprietary platform technology, 3baseTM. Genetic Signatures designs and manufactures a suite of real-time Polymerase Chain Reaction (PCR) based products for the routine detection of infectious diseases under the EasyScreenTM brand. Genetic Signatures’ proprietary MDx 3baseTM platform technology provides high-volume hospital and pathology laboratories the ability to screen for a wide array of infectious pathogens, with a high degree of specificity, in a rapid throughput (time-to-result) environment. Genetic Signatures’ current target markets are major hospital and pathology laboratories undertaking infectious disease screening.